(Q84243572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Azza Ismail

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Julie Kemp

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Basil Sharrack

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

16 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1771-1772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19609591%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-009-5200-9

2 February 2020

exact match

0 references

cites work

Regulation of integrin activity by MIA.

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab for multiple sclerosis

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

1 reference

12 December 2020

Natalizumab and progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Transcriptional regulation of the alpha 4 integrin subunit gene in the metastatic spread of uveal melanoma

1 reference

12 December 2020

Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation.

1 reference

12 December 2020

Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients

1 reference

12 December 2020

Migration and activation of antigen-specific CD8+ T cells upon in vivo stimulation with allogeneic tumor.

1 reference

12 December 2020

LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides

1 reference

12 December 2020

More on melanoma with transdifferentiation

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020